Studio della funzione piastrinica nei pazienti con sindrome mielodisplastica

Dott.ssa Marchesi Federica

Abstract

Hemorrhagic complications are frequent and among the leading causes of death in patients with myelodysplastic syndromes (MDS) or Myeloid Leukemias. Not only thrombocytopenia, but a Iso p late l et function abnormalities contribute to bleeding tendency of these patients. However, no published studies comprehensively evaluated several parameters of platelet function, including the measurement of the platelet levels of cyclic AMP (cAMP), which is an effective inhibitor of platelet function.

In preliminary studies, it was reported that a patients with chronic myelomonocytic leukemia and a personal history of moderate/severe bleeding had severe abnormalities of platelet aggregation and secretion, which could not be fully explained based on the observed abnormalities of the contents of platelet granules and of thromboxane A2 production, and on the observation that major platelet surface glycoproteins were normally expressed. The levels of intraplatelet cAMP in this patient resulted dramatically increased. Another patient was referred to the Ospedale San Paolo for severe bleeding manifestations and was diagnosed with MDS.

A thorough platelet function evaluation revealed that he had severe abnormalities of platelet function that were comparable to those observed in the previously reported patient with chronic myelomonocytic leukemia. This finding suggested that increased cAMP levels may be an important determinant ofthe bleeding diathesis of these patients. The ai m of this case-contro l study is to comprehensively assess in vitro platelet function of patients with MDS of any IPSS risk category or Myeloid Leukemias, by enrolling 40 patients and 40 sex-age matched healthy subjects. Platelet aggregation and secretion induced by several agonists will be measured by lumiaggregometry; GPVI, and GPib on the platelet membrane and the binding of PAC-1 (a monoclonal antibody binding to activated GPIIB/IIIa) will be measured by flow cytometry; platelet content of beta-thromboglobulin, ADP, ATP and serotonin will be measured by standardized assays; the intraplatelet concentration of cAMP at baseline and after stimulation by PGEl and the serum TXB2 levels will be measured by commerciai ELISA kits. Unravelling the mechanism(s) contributing to the bleeding risk of MDS patients may help improving their management.

Progetto
Risultati

Scarica il progetto in pdf Scarica i risultati in pdf

Commenti chiusi